Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis

Abstract

Purpose: We performed a cost-effectiveness analysis using the PHI (Prostate Health Index), 4Kscore® SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated prostate specific antigen to determine the need for biopsy. Materials and Methods: We developed a decision analytical model in men with elevated prostate specific antigen (3 ng/ml or greater) in which 1 biomarker test was used to determine which hypothetical individuals required biopsy. In the current standard of care strategy all individuals underwent biopsy. Model parameters were derived from a comprehensive review of the literature. Costs were calculated from a health sector perspective and converted into 2017 Unit..